Literature DB >> 23996838

Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment.

Davide Colombi1, Elisa Di Lauro, Mario Silva, Carmelinda Manna, Cristina Rossi, Massimo De Filippo, Maurizio Zompatori, Livia Ruffini, Nicola Sverzellati.   

Abstract

The imaging techniques in patients treated for lung cancer may be challenging to interpret. Radiologists are often asked to evaluate computed tomography (CT) scans after surgery, and this interpretation requires an understanding of both the timing and type of the surgical procedure. However, follow-up strategies are still not well defined. The assessment of tumor response to chemoradiotherapy relies on a tight integration of CT and clinical findings. Positron emission tomography-computed tomography (PET-CT) with fluorodeoxyglucose may help to exclude tumor recurrence when the sole CT scan is equivocal. More efforts are needed to validate the tools for volumetric tumor measurement in routine practice and to demonstrate their superiority compared to the Response Evaluation Criteria in Solid Tumors (RECIST). Familiarity with the assessment of lung cancer perfusion is also important because of the increasing use of cytostatic therapy. In this review, we outlined the imaging assessment of tumor recurrence after surgery and the role of CT, magnetic resonance imaging, and PET-CT in the follow-up after chemotherapy, radiotherapy, and radiofrequency ablation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23996838     DOI: 10.5152/dir.2013.12021

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  3 in total

1.  Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients.

Authors:  Mehdi Taghipour; Charles Marcus; Sara Sheikhbahaei; Esther Mena; Shwetha Prasad; Abhinav K Jha; Lilja Solnes; Rathan M Subramaniam
Journal:  J Nucl Med       Date:  2016-11-03       Impact factor: 10.057

2.  Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT.

Authors:  P-G Qiao; H-T Zhang; J Zhou; M Li; J-L Ma; N Tian; X-D Xing; G-J Li
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

3.  Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort.

Authors:  Yong Song; Chengping Hu; Zhanhong Xie; Lin Wu; Zhengfei Zhu; Chuangzhou Rao; Li Liu; Yuan Chen; Naixin Liang; Jun Chen; Chunhong Hu; Nong Yang; Jie Hu; Weixin Zhao; Gangling Tong; Xiaorong Dong; Di Zheng; Meiling Jin; Jianhua Chen; Meijuan Huang; Yong He; Rafael Rosell; Giuseppe Lippi; Mari Mino-Kenudson; Han Han-Zhang; Xinru Mao; Lu Zhang; Hao Liu; John K Field; Shannon Chuai; Junyi Ye; Yusheng Han; Shun Lu
Journal:  Transl Lung Cancer Res       Date:  2020-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.